Par to test each batch of megestrol acetate for microbial contamination following FDA warning letter.
PAR MEGESTROL ACETATE MICROBIAL TESTING ON EVERY FIFTH BATCH WAS INADEQUATE in 1996 to prevent product contamination, FDA told the company in a Jan. 10 warning letter. There was "no assurance that every batch" of Par megestrol acetate 20 mg and 40 mg tabs made during the first nine months of 1996 "met internal microbial specifications, since testing was conducted on every fifth batch produced between Feb. 8 to March 25, March 30 to May 9 and May 28 to June 15, 1996," FDA told the company.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth